|Bid||86.82 x 1500|
|Ask||86.86 x 8800|
|Day's Range||84.50 - 87.38|
|52 Week Range||65.25 - 146.30|
|Beta (5Y Monthly)||1.02|
|PE Ratio (TTM)||26.47|
|Earnings Date||Nov 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||107.55|
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announces today an increase in its financial guidance for the financial year 2020 after preliminary completion of the latest evaluation of MorphoSys' financial performance.
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 19, 2020 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC.
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR AUSTRALIA, SOUTH AFRICA, JAPAN OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWPLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 13, 2020 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today successfully placed unsubordinated, unsecured convertible bonds due 2025 in an aggregate principal amount of EUR 325 million.